Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma

Cancer

Volumn 94, Issue 8, 2002, Pages 2185-2191

  Salvesen, Helga B ^a,b   Stefansson, Ingunn ^a   Kalvenes, May Britt ^a   Das, Soma ^c   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Endometrial carcinoma; Histologic type; Metastasis; Prognosis; PTEN expression

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; PHOSPHORIC MONOESTER HYDROLASES; PLOIDIES; PTEN PHOSPHOHYDROLASE; S PHASE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 0037089643     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10434     Document Type: Article

References (25)

1. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
2. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
3. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
4. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN
5. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
6. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
7. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers
8. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies
9. PTEN1 is frequently mutated in primary endometrial carcinomas
10. PTEN/MMAC1 mutations in endometrial cancers
11. Molecular identification of latent precancers in histologically normal endometrium
12. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis
13. Identification of highrisk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas
14. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: A population-based endometrial carcinoma study
15. Flow cytometric deoxyribonucleic acid index: A prognostic factor in endometrial carcinoma
16. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
17. Methylation of hMLH1 in a population-based series of endometrial carcinomas
18. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
19. Recurrence of endometrial carcinoma and the value of routine follow up
20. Genetic instability of microsatellites in endometrial carcinoma
21. PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases
22. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics
23. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
24. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma
25. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers